SOLV Quote, Financials, Valuation and Earnings

Milestone Scientific has a net margin of 1.49% compared to Solventum's net margin of -58.13%. Solventum's return on equity of 9.76% beat Milestone Scientific's return on equity of -61.33%.

Solventum has a consensus price target of $80.89, signalling upside risk potential of 24.57%. On the other hand Milestone Scientific has an analysts' consensus of -- which suggests that it could grow by 133.52%. Given that Milestone Scientific has higher upside potential than Solventum, analysts believe Milestone Scientific is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.429%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Milestone Scientific quarterly revenues of $2.5M. Solventum's net income of $31M is higher than Milestone Scientific's net income of -$1.5M. Notably, Solventum's price-to-earnings ratio is 23.61x while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.37x versus 8.39x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of 1.49% compared to Solventum's net margin of 0.18%. Solventum's return on equity of 9.76% beat Envista Holdings's return on equity of -32.33%.

Solventum has a consensus price target of $80.89, signalling upside risk potential of 24.57%. On the other hand Envista Holdings has an analysts' consensus of $20.25 which suggests that it could grow by 33.49%. Given that Envista Holdings has higher upside potential than Solventum, analysts believe Envista Holdings is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Envista Holdings has a beta of 1.120, suggesting its more volatile than the S&P 500 by 12.044%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Envista Holdings quarterly revenues of $652.9M. Solventum's net income of $31M is higher than Envista Holdings's net income of $1.2M. Notably, Solventum's price-to-earnings ratio is 23.61x while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.37x versus 1.04x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific has a net margin of 1.49% compared to Solventum's net margin of 16.06%. Solventum's return on equity of 9.76% beat Thermo Fisher Scientific's return on equity of 13.27%.

Solventum has a consensus price target of $80.89, signalling upside risk potential of 24.57%. On the other hand Thermo Fisher Scientific has an analysts' consensus of $628.36 which suggests that it could grow by 44.54%. Given that Thermo Fisher Scientific has higher upside potential than Solventum, analysts believe Thermo Fisher Scientific is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Thermo Fisher Scientific has a beta of 0.865, suggesting its less volatile than the S&P 500 by 13.532%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific offers a yield of 0.37% to investors and pays a quarterly dividend of $0.43 per share. Solventum pays -- of its earnings as a dividend. Thermo Fisher Scientific pays out 9.2% of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Solventum quarterly revenues are $2.1B, which are smaller than Thermo Fisher Scientific quarterly revenues of $11.4B. Solventum's net income of $31M is lower than Thermo Fisher Scientific's net income of $1.8B. Notably, Solventum's price-to-earnings ratio is 23.61x while Thermo Fisher Scientific's PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.37x versus 3.89x for Thermo Fisher Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of 1.49% compared to Solventum's net margin of -47.51%. Solventum's return on equity of 9.76% beat Dentsply Sirona's return on equity of -32.39%.

Solventum has a consensus price target of $80.89, signalling upside risk potential of 24.57%. On the other hand Dentsply Sirona has an analysts' consensus of $18.57 which suggests that it could grow by 42.64%. Given that Dentsply Sirona has higher upside potential than Solventum, analysts believe Dentsply Sirona is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.918, suggesting its less volatile than the S&P 500 by 8.232%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.92% to investors and pays a quarterly dividend of $0.16 per share. Solventum pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Dentsply Sirona quarterly revenues of $905M. Solventum's net income of $31M is higher than Dentsply Sirona's net income of -$430M. Notably, Solventum's price-to-earnings ratio is 23.61x while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.37x versus 0.70x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.